Antibody Pharming in Transgenic Plants: An Overview

Authors

  • Ajit Singh Professor (Immunology), Department of Veterinary Microbiology, Lala Lajpat Rai University of Veterinary & Animal Sciences, Hisar, Haryana India

DOI:

https://doi.org/10.37591/rrjoi.v3i3.1180

Abstract

Antibodies (Abs) are secreted large-sized glycoprotein products of terminally differentiated B cells in vertebrate species and since their discovery during 1890s, they have been widely used for diagnosis, prevention and treatment of diseases, epidemiology and life-science research. They have been traditionally produced in large amounts by repeated immunization of animals. Various techniques for production of full-length and fragments of antibody that have been introduced later are: (i). hybridoma technology during 1970s, (ii). recombinant DNA technologies for Ab production in heterologous expression systems during 1980s, and (iii). technologies for “antibody display” libraries since 1990s. In addition, cost-effective agriculture-scale Abs have been produced in transgenic plants since 1990s. Antibody “pharming” (pharmaceutical farming) is a portmanteau term used for agriculture-scale production of antibodies as pharmaceutical in transgenic plants. Attempts are being made to overcome various present-day bottlenecks such as low yield, costly downstream processing, biosecurity risks, etc. First generation “plantibodies” (Abs produced in plants) specific to various clinically important antigens have now reached commercialization stage. An overview of the field of antibody pharming is presented.

 

Keywords: Antibodies, hybridoma, pharming, plantibodies

Downloads

Published

2019-04-02

Issue

Vol. 3 No. 3 (2013)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.